Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc. (VIRX): 1 pipeline candidate · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.9 months
D/E -4.32 · 0% dilution
Lead: Phase 1
1 candidate
N/A
N/A
A transparent, data-derived signal for Viracta Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$13.1M
Quarterly Burn
$7.1M
Runway
8.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| nana-val | Phase 1 |
Frequently asked questions
How many drug candidates are in Viracta Therapeutics, Inc.'s pipeline?
Viracta Therapeutics, Inc. (VIRX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Viracta Therapeutics, Inc.'s lead drug candidate?
Viracta Therapeutics, Inc.'s most advanced tracked candidate is nana-val (Phase 1) for EBV-positive recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) and other EBV+ solid tumors.
What is Viracta Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Viracta Therapeutics, Inc. has approximately 8.9 months of cash runway.
Who is the CEO of Viracta Therapeutics, Inc.?
California Table is the chief executive officer of Viracta Therapeutics, Inc. (VIRX).
Get the full picture on Viracta Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.